№ files_lp_4_process_2_89768
File format: docx Character count: 3094 File size: 31 KB
This is a formal request from a healthcare provider to a health insurance company, advocating for coverage of a specific medical treatment, UPLIZNA, for a patient diagnosed with neuromyelitis optica spectrum disorder (NMOSD).
Year: [Year]
Region / city: [Region/City]
Topic: Health insurance, medical treatment
Document type: Medical letter, insurance request
Organization / institution: [Health insurance company]
Target audience: Health insurance company, medical professionals
Effective period: [Effective period if mentioned]
Approval date: [Approval date if mentioned]
Modification date: [Modification date if mentioned]
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Neuromyelitis Optica in Children: A Rare Case Report
Year: None
Region / City: None
Theme: Neurology
Document Type: Case Report
Organization / Institution: None
Author: Jethro Budiman
Target Audience: Medical Professionals
Period of Validity: None
Approval Date: None
Date of Changes: None
Letter of Medical Necessity for UPLIZNA® (inebilizumab-cdon)
Note: Date
Diagnosis: G36.0, neuromyelitis optica [Devic]
Treatment: UPLIZNA® (inebilizumab-cdon), injection, 1 mg
Reason for request: Medical necessity for treatment of neuromyelitis optica spectrum disorder (NMOSD) with UPLIZNA
Enclosures: Prescribing Information, clinical notes, FDA approval letter, patient relapse history, test results, etc.
Uplizna 100 mg concentrate for solution for infusion
Year: 2023
Region / city: Europe
Topic: Neurology, Immunology
Document type: Product Information
Author: European Medicines Agency
Target audience: Healthcare professionals
Period of validity: Not specified
Approval date: Not specified
Date of changes: Not specified
Topics: NMOSD Neuromyelitis UPLIZNA